Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Maillet

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 31, 2016
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal MesotheliomasNoémie Leblay, Frédéric Leprêtre, Nolwenn Le Stang, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
Future Oncology (London, England)|January 13, 2017
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenibMévidette El-Madani, Olivier Colomban, Michel Tod, et al.
Clinical Pharmacokinetics|July 4, 2024
Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI TrialJérôme Alexandre, Stephane Oudard, Lisa Golmard, et al.
The Lancet Regional Health. Europe|August 22, 2024
Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort studyAntonio Farina, Macarena Villagrán-García, Anthony Fourier, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
European Urology|May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderBernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
The Lancet. Oncology|April 7, 2022
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialYann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 31, 2016
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal MesotheliomasNoémie Leblay, Frédéric Leprêtre, Nolwenn Le Stang, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
Future Oncology (London, England)|January 13, 2017
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenibMévidette El-Madani, Olivier Colomban, Michel Tod, et al.
Clinical Pharmacokinetics|July 4, 2024
Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI TrialJérôme Alexandre, Stephane Oudard, Lisa Golmard, et al.
The Lancet Regional Health. Europe|August 22, 2024
Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort studyAntonio Farina, Macarena Villagrán-García, Anthony Fourier, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|March 22, 2023
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
European Urology|May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderBernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
The Lancet. Oncology|April 7, 2022
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialYann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, et al.
Pageof 7